Amylyx - Phoenix
A randomized, double-blind, placebo-controlled, multicenter phase III study evaluating the safety and efficacy of AMX0035 versus placebo for 48 weeks of treatment in adult patients with amyotrophic lateral sclerosis (ALS).
AMX0035 consists of a combination of two compounds, phenyl butyrate and taurursodiol. It is being studied to see if the combination of these two substances can inhibit the disease.
You have a 60% chance of getting AMX0035 and a 40% chance of getting placebo.
The study drug comes in a sachet that must be dissolved in water; you will start with 1 sachet per day. After 14-21 days this can be increased to 2 sachets per day, this only after contacting the research center by phone.
The study lasts about 1 year, after that period you can continue to participate in an open label study.
